Evidence map›Paper›PMID 38534939›Full record

ReviewCurrent oncology (Toronto, Ont.)2024

Kim N Chi, Steven M Yip, Glenn Bauman, Stephan Probst, Urban Emmenegger, Christian K Kollmannsberger, Patrick Martineau, Tamim Niazi, Frédéric Pouliot, Ricardo Rendon and 3 more

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current oncology (Toronto, Ont.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03511664 (VISION), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03511664 phase3completednot on this map

VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)

TypeinterventionalSponsorEndocyteRan2018 to 2023Enrolled861ConditionsProstate CancerArms177Lu-PSMA-617, Best supportive/best standard of care
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trajectory timelines and treatment efficacy ofCanadian Urological Association journal = Journal de l'Association des urologues du Canada · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Molecules (Basel, Switzerland) · 2025
    Review
  6. Framework to calculateMedical physics · 2025
    Article
  7. Exploring the Therapeutic Potential ofInternational journal of molecular sciences · 2025
    Article
  8. Review
  9. Review
  10. Assessment ofJournal of medical physics
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 1 country.

Kim N ChiDepartment of Medical Oncology, BC Cancer-Vancouver, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.ORCID 0000-0002-3782-7226
Steven M YipDepartment of Oncology, Tom Baker Cancer Centre and Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada.
Glenn BaumanLondon Regional Cancer Program, Department of Oncology, Western University, London, ON N6A 5W9, Canada.
Stephan ProbstDepartment of Nuclear Medicine, Jewish General Hospital, McGill University, Montreal, QC H3A 0G4, Canada.ORCID 0000-0002-8692-7573
Urban EmmeneggerDepartment of Medicine, Odette Cancer Centre, University of Toronto, Toronto, ON M5S 1A8, Canada.ORCID 0000-0002-3178-1896
Christian K KollmannsbergerDepartment of Medical Oncology, BC Cancer-Vancouver, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
Patrick MartineauDepartment of Radiology, BC Cancer-Vancouver, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
Tamim NiaziDepartment of Radiation Oncology, Jewish General Hospital, McGill University, Montréal, QC H3T 1E2, Canada.
Frédéric PouliotDepartment of Urology, Centre Hospitalier Universitaire de Québec, Université Laval, Québec, QC G1V 0A6, Canada.ORCID 0000-0002-6651-1079
Ricardo RendonDepartment of Urology, Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS B3H 4R2, Canada.
Sebastien J HotteDepartment of Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, ON L8S 4L8, Canada.ORCID 0000-0001-9286-1972
David T LaidleyDepartment of Medical Imaging-Nuclear Medicine, London Health Sciences Centre, Western University, London, ON N6A 3K7, Canada.
Fred SaadDivision of Urology, Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montréal, QC H2X 0A9, Canada.ORCID 0000-0003-2986-5617
University of British Columbia · CAJewish General Hospital · CAWestern University · CACentre Hospitalier de l’Université de Montréal · CACentre hospitalier universitaire de Québec · CADalhousie University · CAJuravinski Cancer Centre · CAUniversity of Calgary · CAUniversity of Toronto · CA

Funding

Novartis (Canada) Not applicable
6 · The paper itself

Abstract

Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer and a therapeutic target. Lutetium-177 (

Indexed as

DipeptidesHeterocyclic Compounds, 1-RingProstatic Neoplasms, Castration-ResistantCanadaHumansMaleProspective StudiesProstate-Specific AntigenDipeptidesHeterocyclic Compounds, 1-RingProstate-Specific AntigenPSMA-617177Lu-PSMA-617177Lu vipivotide tetraxetanmCRPCprostate cancerradioligand therapy

Identifiers

PMID38534939
PMCPMC10969693
OpenAlexW4392587677

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.